Cardenolide-Engineered Extracellular Vesicles Augment Drug Uptake and Cytotoxicity in Non-small Cell Lung Cancer...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Cancer therapy requires targeted drug delivery to minimize side effects and reduce dosages.
• The sodium-potassium ATPase (Na+/K+-ATPase) is overexpressed in A549 non-small cell lung cancer (NSCLC) and is a potential therapeutic target.
• Cardiac glycosides (CGs) inhibit Na+/K+-ATPase, and extracellular vesicles (EVs) are promising biocompatible nanocarriers.

Purpose of the Study:

• To develop a target-oriented nanocarrier system for NSCLC by modifying A549 cell-derived EVs with a CG derivative.
• To evaluate the efficacy of these modified EVs as a drug delivery system for A549 NSCLC.

Main Methods:

• A549 cell-derived EVs were isolated and characterized.
• Surface modification of EVs was achieved by linking 3β-azido-3-deoxydigitoxigenin (CA) via click chemistry.
• Na+/K+-ATPase activity was measured to confirm conjugation; co-localization was verified using confocal microscopy. Doxorubicin-loaded EVs were tested for cytotoxicity.

Main Results:

• Successful conjugation of CA to A549 EVs was confirmed by inhibition of Na+/K+-ATPase activity.
• CA-modified EVs showed co-localization with Na+/K+-ATPase in A549 cells.
• Doxorubicin-loaded, CA-modified EVs reduced A549 cell viability by 45% within 48 hours.

Conclusions:

• A549 cell-derived EVs modified with a CG derivative (CA) serve as an effective target-oriented nanocarrier system.
• This novel nanocarrier system demonstrates potential for targeted delivery of anti-cancer drugs like doxorubicin in NSCLC.
• Further research into this approach could lead to improved cancer therapeutics with reduced systemic toxicity.